Almirall confers the 2003 Pharmacology Award
Within the field of pharmacology, this award is distinguished for recognising a future research project as opposed to a completed project
Today at the 25th Congress of the Spanish Pharmacology Society that is taking place in Cadiz from 8 to 11 of October, the 2003 Pharmacology Award is being conferred. Jointly promoted by Almirall, the first Spanish pharmaceutical multinational, and the Spanish Pharmacology Society (SEF), it is the first award to recognise the quality of future research projects within the field of pharmacology in Spain.
With a prize of 9,000 euros, the winner project is entitled "Cardiovascular and antithrombotic effects of resveratrol’s Cis and Trans isomers. Comparative study" by Dr Francisco Orallo from the University of Santiago de Compostela. The project will be carried out during 2003-2004, and the results will be presented in the next congress of the Spanish Pharmacology Society.
The jury has been composed by Dr Felipe Sánchez de la Cuesta, president of SEF, Dr Jesús Llenas and Dr Amadeu Gavaldá, both from Almirall. Dr Gavaldá explains: "to value this award we have taken into account the originality and topicality of the project, its structure, and the difficulty in conducting the study, as well as the new information that could be obtained through its results".
The evaluation of the projects submitted was carried out through an independent scoring process as well as through consensus among the jury members.
The results of the 2002 Pharmacology Award will be published during the event by Dr María J. Sanz.
Almirall, the first Spanish pharmaceutical multinational
The main aim of Almirall, the first Spanish pharmaceutical multinational, is to provide society with innovative drugs to combat discomfort and disease, thus helping to improve health and quality of life. To this end, it constantly devotes the maximum human and financial resources to researching new products.
The company’s main research fields fall within the areas related to the treatment of asthma, allergies, bronchitis, atopic dermatitis, arthritis and gastrointestinal disorders.
The company plans to invest in R&D around 490 million euros in the next five years, and the total sales forecasts for 2003 are projected to reach 946.7 million euros. Its estimated staff for 2003 is of 3,256 people, of whom 532 are related to R&D activities.
The company also has five R&D centres and six manufacturing plants, as well as branch offices in the main cities of Spain and subsidiaries in Europe and Latin America.
Its annual production forecast for this year is over 94 million units, and products resulting from its own R&D are marketed in over 80 countries around the world.